Common Contracts
2 similar Assignment and License Agreement contracts by Harpoon Therapeutics, Inc.
EX-10.14 20 d630873dex1014.htm EX-10.14 [ ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. FIRST...Assignment and License Agreement • May 5th, 2020 • California
This First Amended and Restated Assignment and License Agreement (this “Agreement”) is entered into as of October 19, 2018 (the “Amendment Date”), by and between Werewolf Therapeutics, Inc., a Delaware corporation, with a place of business c/o MPM Capital, 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080 (“Werewolf”), and Harpoon Therapeutics, Inc., a Delaware corporation with a place of business at 4000 Shoreline Court, Suite 250, South San Francisco, CA 94080 (“Harpoon”).
FIRST AMENDED AND RESTATED ASSIGNMENT AND LICENSE AGREEMENTAssignment and License Agreement • October 24th, 2018 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This First Amended and Restated Assignment and License Agreement (this “Agreement”) is entered into as of October 19, 2018 (the “Amendment Date”), by and between Werewolf Therapeutics, Inc., a Delaware corporation, with a place of business c/o MPM Capital, 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080 (“Werewolf”), and Harpoon Therapeutics, Inc., a Delaware corporation with a place of business at 4000 Shoreline Court, Suite 250, South San Francisco, CA 94080 (“Harpoon”).
